Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | UNG | P13051 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15678985 | 0.85 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1POLBSRCTTR | |
| SCHEMBL3649236 | 0.85 | ALDH1A1 (0.42) | ALDH1A1NFE2L2UNGFBP1CYP2A6 | |
| SCHEMBL6854130 | 0.83 | ALDH1A1 (0.48) | ALDH1A1NFE2L2UNGFBP1CYP2A6 | |
| SCHEMBL29425705 | 0.83 | FBP1 (0.56) | ALDH1A1NFE2L2FBP1L3MBTL1POLB | |
| SCHEMBL67201 | 0.83 | FBP1 (0.56) | ALDH1A1NFE2L2FBP1L3MBTL1POLB | |
| SCHEMBL6848985 | 0.83 | ALDH1A1 (0.48) | ALDH1A1NFE2L2UNGFBP1CYP2A6 | |
| SCHEMBL309484 | 0.83 | ALDH1A1 (0.48) | ALDH1A1NFE2L2UNGCYP2A6L3MBTL1 | |
| SCHEMBL29846591 | 0.83 | ALDH1A1 (0.48) | ALDH1A1NFE2L2UNGCYP2A6L3MBTL1 | |
| Acetaldehyde SCHEMBL28151033 | 0.82 | NFE2L2 (0.54) | ALDH1A1NFE2L2FBP1L3MBTL1POLB | |
| SCHEMBL6855120 | 0.82 | ALDH1A1 (0.47) | ALDH1A1NFE2L2UNGFBP1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2022156792-A1 | HETEROCYCLIC COMPOUNDS AS SOS1 INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-07-28 | — | — | WO | disclosed |
| US-8426448-B2 | 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | ELI LILLY AND COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426448-B2 | 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | ELI LILLY AND COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426448-B2 | 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | ELI LILLY AND COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8168659-B2 | 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators | ELI LILLY AND COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168659-B2 | 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators | ELI LILLY AND COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2009131814-A2 | 1,5-DIPHENYL-PYRROLIDIN-2-ONE COMPOUNDS AS CB-1 LIGANDS | ELI LILLY AND COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-2094684-A2 | 1,5-DIPHENYL-3-BENZYLAMINO-1,5-DIHYDROPYRROLIDIN 2-ONES AS CB1 RECEPTOR MODULATORS | Eli Lilly & Company (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009024615-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008070306-A2 | 1,5-DIPHENYL-3-BENZYLAMIN0-1,5-DIHYDR0PYRR0LIDIN-2-0NE AS CB1 RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070306-A2 | 1,5-DIPHENYL-3-BENZYLAMIN0-1,5-DIHYDR0PYRR0LIDIN-2-0NE AS CB1 RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | ALDH1A1 2720/4885NFE2L2 359/4885UNG 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.